查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1873405

胰臟癌诊断：全球市场份额和排名、总收入和需求预测（2025-2031年）

Pancreatic Cancer Diagnostic - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 108 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球胰臟癌诊断市场规模估计为 65.72 亿美元，预计到 2031 年将成长至 106.9 亿美元，2025 年至 2031 年的复合年增长率为 7.3%。

胰臟癌诊断是指用于检测和识别不同阶段胰臟癌的方法和技术。这包括CT、MRI和内视镜超音波（EUS）等影像学技术，以及生物标记检测（例如CA 19-9）、基因检测和组织切片检查等分子诊断方法。由于胰臟癌早期通常无症状，因此早期发现极具挑战性，但准确的诊断工具对于适当的治疗和提高存活率至关重要。

全球胰臟癌发生率的不断上升以及对早期精准检测的迫切需求，推动了胰臟癌诊断市场的发展。由于胰臟癌早期往往无症状，因此常常在晚期才被确诊，这促使人们对分子生物标记（例如CA 19-9、KRAS突变）、液态生物检体、次世代定序（NGS）和人工智慧辅助成像工具等先进诊断解决方案的需求不断增长。政府对癌症研究的资助以及精准肿瘤学倡议的兴起，也推动了创新诊断平台的开发和广泛应用。

儘管技术不断进步，市场仍面临许多挑战。由于缺乏特异性症状以及现有生物标记的敏感性和特异性有限，胰臟癌的早期检测仍然十分困难。基因定序和影像学等先进诊断方法的高成本限制了其普及，尤其是在中低收入社区。此外，监管壁垒、严格的报销政策以及将多组体学数据整合到临床工作流程中的复杂性也阻碍了尖端诊断解决方案的广泛应用。

本报告旨在按地区/国家、类型和应用对全球胰腺癌诊断市场进行全面分析，重点关注总收入、市场份额和主要企业的排名。

本报告以销售收入为指标，对胰腺癌诊断市场规模、估算和预测进行了呈现，以2024年为基准年，并涵盖了2020年至2031年的历史数据和预测数据。定量和定性分析将帮助读者制定业务和成长策略，评估市场竞争，分析自身在当前市场中的地位，并就胰腺癌诊断做出明智的商业决策。

市场区隔

公司

  • Siemens
  • GE Healthcare
  • Roche
  • Philips Healthcare
  • Danaher
  • Canon Medical Systems
  • Abbott
  • Fujifilm
  • Qiagen
  • Myriad Genetics
  • Thermo Fisher Scientific
  • Dian Diagnostic

按类型分類的细分市场

  • 影像诊断
  • 肿瘤生物标记
  • 切片检查
  • 其他的

应用领域

  • 医院
  • 诊所
  • 其他的

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Pancreatic Cancer Diagnostic was estimated to be worth US$ 6572 million in 2024 and is forecast to a readjusted size of US$ 10690 million by 2031 with a CAGR of 7.3% during the forecast period 2025-2031.

Pancreatic cancer diagnostics refer to the methods and technologies used to detect and identify pancreatic cancer at various stages. These include imaging techniques such as CT, MRI, and endoscopic ultrasound (EUS), as well as molecular diagnostics like biomarker testing (e.g., CA 19-9), genetic testing, and tissue biopsy. Early detection is challenging due to the cancer's asymptomatic nature in early stages, but accurate diagnostic tools are essential for timely treatment and improved survival outcomes.

The pancreatic cancer diagnostic market is driven by the increasing global incidence of pancreatic cancer and the urgent need for early and accurate detection. As pancreatic cancer is often diagnosed at an advanced stage due to its asymptomatic progression, there is growing demand for advanced diagnostic solutions such as molecular biomarkers (e.g., CA 19-9, KRAS mutations), liquid biopsy, next-generation sequencing (NGS), and AI-assisted imaging tools. Government funding for cancer research and the rise of precision oncology initiatives are also encouraging the development and adoption of innovative diagnostic platforms.

Despite technological progress, the market faces significant challenges. Early detection of pancreatic cancer remains difficult due to the lack of specific symptoms and the limited sensitivity and specificity of current biomarkers. High costs associated with advanced diagnostic methods, such as genetic sequencing and imaging, can restrict accessibility, particularly in low- and middle-income regions. Additionally, regulatory hurdles, limited reimbursement policies, and the complexity of integrating multi-omics data into clinical workflows pose barriers to widespread implementation of cutting-edge diagnostic solutions.

This report aims to provide a comprehensive presentation of the global market for Pancreatic Cancer Diagnostic, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Pancreatic Cancer Diagnostic by region & country, by Type, and by Application.

The Pancreatic Cancer Diagnostic market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pancreatic Cancer Diagnostic.

Market Segmentation

By Company

  • Siemens
  • GE Healthcare
  • Roche
  • Philips Healthcare
  • Danaher
  • Canon Medical Systems
  • Abbott
  • Fujifilm
  • Qiagen
  • Myriad Genetics
  • Thermo Fisher Scientific
  • Dian Diagnostic

Segment by Type

  • Imaging
  • Tumor Biomarker
  • Biopsy
  • Others

Segment by Application

  • Hospitals
  • Clinics
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Pancreatic Cancer Diagnostic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Pancreatic Cancer Diagnostic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Pancreatic Cancer Diagnostic in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Pancreatic Cancer Diagnostic Product Introduction
  • 1.2 Global Pancreatic Cancer Diagnostic Market Size Forecast (2020-2031)
  • 1.3 Pancreatic Cancer Diagnostic Market Trends & Drivers
    • 1.3.1 Pancreatic Cancer Diagnostic Industry Trends
    • 1.3.2 Pancreatic Cancer Diagnostic Market Drivers & Opportunity
    • 1.3.3 Pancreatic Cancer Diagnostic Market Challenges
    • 1.3.4 Pancreatic Cancer Diagnostic Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Pancreatic Cancer Diagnostic Players Revenue Ranking (2024)
  • 2.2 Global Pancreatic Cancer Diagnostic Revenue by Company (2020-2025)
  • 2.3 Key Companies Pancreatic Cancer Diagnostic Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Pancreatic Cancer Diagnostic Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Pancreatic Cancer Diagnostic
  • 2.6 Pancreatic Cancer Diagnostic Market Competitive Analysis
    • 2.6.1 Pancreatic Cancer Diagnostic Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Pancreatic Cancer Diagnostic Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pancreatic Cancer Diagnostic as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Imaging
    • 3.1.2 Tumor Biomarker
    • 3.1.3 Biopsy
    • 3.1.4 Others
  • 3.2 Global Pancreatic Cancer Diagnostic Sales Value by Type
    • 3.2.1 Global Pancreatic Cancer Diagnostic Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Pancreatic Cancer Diagnostic Sales Value, by Type (2020-2031)
    • 3.2.3 Global Pancreatic Cancer Diagnostic Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospitals
    • 4.1.2 Clinics
    • 4.1.3 Others
  • 4.2 Global Pancreatic Cancer Diagnostic Sales Value by Application
    • 4.2.1 Global Pancreatic Cancer Diagnostic Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Pancreatic Cancer Diagnostic Sales Value, by Application (2020-2031)
    • 4.2.3 Global Pancreatic Cancer Diagnostic Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Pancreatic Cancer Diagnostic Sales Value by Region
    • 5.1.1 Global Pancreatic Cancer Diagnostic Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Pancreatic Cancer Diagnostic Sales Value by Region (2020-2025)
    • 5.1.3 Global Pancreatic Cancer Diagnostic Sales Value by Region (2026-2031)
    • 5.1.4 Global Pancreatic Cancer Diagnostic Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Pancreatic Cancer Diagnostic Sales Value, 2020-2031
    • 5.2.2 North America Pancreatic Cancer Diagnostic Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Pancreatic Cancer Diagnostic Sales Value, 2020-2031
    • 5.3.2 Europe Pancreatic Cancer Diagnostic Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Pancreatic Cancer Diagnostic Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Pancreatic Cancer Diagnostic Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Pancreatic Cancer Diagnostic Sales Value, 2020-2031
    • 5.5.2 South America Pancreatic Cancer Diagnostic Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Pancreatic Cancer Diagnostic Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Pancreatic Cancer Diagnostic Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Pancreatic Cancer Diagnostic Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Pancreatic Cancer Diagnostic Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Pancreatic Cancer Diagnostic Sales Value, 2020-2031
    • 6.3.2 United States Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Pancreatic Cancer Diagnostic Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Pancreatic Cancer Diagnostic Sales Value, 2020-2031
    • 6.4.2 Europe Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Pancreatic Cancer Diagnostic Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Pancreatic Cancer Diagnostic Sales Value, 2020-2031
    • 6.5.2 China Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Pancreatic Cancer Diagnostic Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Pancreatic Cancer Diagnostic Sales Value, 2020-2031
    • 6.6.2 Japan Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Pancreatic Cancer Diagnostic Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Pancreatic Cancer Diagnostic Sales Value, 2020-2031
    • 6.7.2 South Korea Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Pancreatic Cancer Diagnostic Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Pancreatic Cancer Diagnostic Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Pancreatic Cancer Diagnostic Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Pancreatic Cancer Diagnostic Sales Value, 2020-2031
    • 6.9.2 India Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Pancreatic Cancer Diagnostic Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Siemens
    • 7.1.1 Siemens Profile
    • 7.1.2 Siemens Main Business
    • 7.1.3 Siemens Pancreatic Cancer Diagnostic Products, Services and Solutions
    • 7.1.4 Siemens Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Siemens Recent Developments
  • 7.2 GE Healthcare
    • 7.2.1 GE Healthcare Profile
    • 7.2.2 GE Healthcare Main Business
    • 7.2.3 GE Healthcare Pancreatic Cancer Diagnostic Products, Services and Solutions
    • 7.2.4 GE Healthcare Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
    • 7.2.5 GE Healthcare Recent Developments
  • 7.3 Roche
    • 7.3.1 Roche Profile
    • 7.3.2 Roche Main Business
    • 7.3.3 Roche Pancreatic Cancer Diagnostic Products, Services and Solutions
    • 7.3.4 Roche Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Roche Recent Developments
  • 7.4 Philips Healthcare
    • 7.4.1 Philips Healthcare Profile
    • 7.4.2 Philips Healthcare Main Business
    • 7.4.3 Philips Healthcare Pancreatic Cancer Diagnostic Products, Services and Solutions
    • 7.4.4 Philips Healthcare Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Philips Healthcare Recent Developments
  • 7.5 Danaher
    • 7.5.1 Danaher Profile
    • 7.5.2 Danaher Main Business
    • 7.5.3 Danaher Pancreatic Cancer Diagnostic Products, Services and Solutions
    • 7.5.4 Danaher Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Danaher Recent Developments
  • 7.6 Canon Medical Systems
    • 7.6.1 Canon Medical Systems Profile
    • 7.6.2 Canon Medical Systems Main Business
    • 7.6.3 Canon Medical Systems Pancreatic Cancer Diagnostic Products, Services and Solutions
    • 7.6.4 Canon Medical Systems Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Canon Medical Systems Recent Developments
  • 7.7 Abbott
    • 7.7.1 Abbott Profile
    • 7.7.2 Abbott Main Business
    • 7.7.3 Abbott Pancreatic Cancer Diagnostic Products, Services and Solutions
    • 7.7.4 Abbott Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Abbott Recent Developments
  • 7.8 Fujifilm
    • 7.8.1 Fujifilm Profile
    • 7.8.2 Fujifilm Main Business
    • 7.8.3 Fujifilm Pancreatic Cancer Diagnostic Products, Services and Solutions
    • 7.8.4 Fujifilm Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Fujifilm Recent Developments
  • 7.9 Qiagen
    • 7.9.1 Qiagen Profile
    • 7.9.2 Qiagen Main Business
    • 7.9.3 Qiagen Pancreatic Cancer Diagnostic Products, Services and Solutions
    • 7.9.4 Qiagen Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Qiagen Recent Developments
  • 7.10 Myriad Genetics
    • 7.10.1 Myriad Genetics Profile
    • 7.10.2 Myriad Genetics Main Business
    • 7.10.3 Myriad Genetics Pancreatic Cancer Diagnostic Products, Services and Solutions
    • 7.10.4 Myriad Genetics Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Myriad Genetics Recent Developments
  • 7.11 Thermo Fisher Scientific
    • 7.11.1 Thermo Fisher Scientific Profile
    • 7.11.2 Thermo Fisher Scientific Main Business
    • 7.11.3 Thermo Fisher Scientific Pancreatic Cancer Diagnostic Products, Services and Solutions
    • 7.11.4 Thermo Fisher Scientific Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Thermo Fisher Scientific Recent Developments
  • 7.12 Dian Diagnostic
    • 7.12.1 Dian Diagnostic Profile
    • 7.12.2 Dian Diagnostic Main Business
    • 7.12.3 Dian Diagnostic Pancreatic Cancer Diagnostic Products, Services and Solutions
    • 7.12.4 Dian Diagnostic Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Dian Diagnostic Recent Developments

8 Industry Chain Analysis

  • 8.1 Pancreatic Cancer Diagnostic Industrial Chain
  • 8.2 Pancreatic Cancer Diagnostic Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Pancreatic Cancer Diagnostic Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Pancreatic Cancer Diagnostic Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Pancreatic Cancer Diagnostic Market Trends
  • Table 2. Pancreatic Cancer Diagnostic Market Drivers & Opportunity
  • Table 3. Pancreatic Cancer Diagnostic Market Challenges
  • Table 4. Pancreatic Cancer Diagnostic Market Restraints
  • Table 5. Global Pancreatic Cancer Diagnostic Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Pancreatic Cancer Diagnostic Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Pancreatic Cancer Diagnostic Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Pancreatic Cancer Diagnostic Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Pancreatic Cancer Diagnostic
  • Table 10. Global Pancreatic Cancer Diagnostic Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pancreatic Cancer Diagnostic as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Pancreatic Cancer Diagnostic Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Pancreatic Cancer Diagnostic Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Pancreatic Cancer Diagnostic Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Pancreatic Cancer Diagnostic Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Pancreatic Cancer Diagnostic Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Pancreatic Cancer Diagnostic Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Pancreatic Cancer Diagnostic Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Pancreatic Cancer Diagnostic Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Pancreatic Cancer Diagnostic Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Pancreatic Cancer Diagnostic Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Pancreatic Cancer Diagnostic Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Pancreatic Cancer Diagnostic Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Pancreatic Cancer Diagnostic Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Pancreatic Cancer Diagnostic Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Pancreatic Cancer Diagnostic Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Pancreatic Cancer Diagnostic Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Pancreatic Cancer Diagnostic Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Pancreatic Cancer Diagnostic Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Siemens Basic Information List
  • Table 32. Siemens Description and Business Overview
  • Table 33. Siemens Pancreatic Cancer Diagnostic Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Pancreatic Cancer Diagnostic Business of Siemens (2020-2025)
  • Table 35. Siemens Recent Developments
  • Table 36. GE Healthcare Basic Information List
  • Table 37. GE Healthcare Description and Business Overview
  • Table 38. GE Healthcare Pancreatic Cancer Diagnostic Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Pancreatic Cancer Diagnostic Business of GE Healthcare (2020-2025)
  • Table 40. GE Healthcare Recent Developments
  • Table 41. Roche Basic Information List
  • Table 42. Roche Description and Business Overview
  • Table 43. Roche Pancreatic Cancer Diagnostic Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Pancreatic Cancer Diagnostic Business of Roche (2020-2025)
  • Table 45. Roche Recent Developments
  • Table 46. Philips Healthcare Basic Information List
  • Table 47. Philips Healthcare Description and Business Overview
  • Table 48. Philips Healthcare Pancreatic Cancer Diagnostic Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Pancreatic Cancer Diagnostic Business of Philips Healthcare (2020-2025)
  • Table 50. Philips Healthcare Recent Developments
  • Table 51. Danaher Basic Information List
  • Table 52. Danaher Description and Business Overview
  • Table 53. Danaher Pancreatic Cancer Diagnostic Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Pancreatic Cancer Diagnostic Business of Danaher (2020-2025)
  • Table 55. Danaher Recent Developments
  • Table 56. Canon Medical Systems Basic Information List
  • Table 57. Canon Medical Systems Description and Business Overview
  • Table 58. Canon Medical Systems Pancreatic Cancer Diagnostic Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Pancreatic Cancer Diagnostic Business of Canon Medical Systems (2020-2025)
  • Table 60. Canon Medical Systems Recent Developments
  • Table 61. Abbott Basic Information List
  • Table 62. Abbott Description and Business Overview
  • Table 63. Abbott Pancreatic Cancer Diagnostic Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Pancreatic Cancer Diagnostic Business of Abbott (2020-2025)
  • Table 65. Abbott Recent Developments
  • Table 66. Fujifilm Basic Information List
  • Table 67. Fujifilm Description and Business Overview
  • Table 68. Fujifilm Pancreatic Cancer Diagnostic Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Pancreatic Cancer Diagnostic Business of Fujifilm (2020-2025)
  • Table 70. Fujifilm Recent Developments
  • Table 71. Qiagen Basic Information List
  • Table 72. Qiagen Description and Business Overview
  • Table 73. Qiagen Pancreatic Cancer Diagnostic Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Pancreatic Cancer Diagnostic Business of Qiagen (2020-2025)
  • Table 75. Qiagen Recent Developments
  • Table 76. Myriad Genetics Basic Information List
  • Table 77. Myriad Genetics Description and Business Overview
  • Table 78. Myriad Genetics Pancreatic Cancer Diagnostic Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Pancreatic Cancer Diagnostic Business of Myriad Genetics (2020-2025)
  • Table 80. Myriad Genetics Recent Developments
  • Table 81. Thermo Fisher Scientific Basic Information List
  • Table 82. Thermo Fisher Scientific Description and Business Overview
  • Table 83. Thermo Fisher Scientific Pancreatic Cancer Diagnostic Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Pancreatic Cancer Diagnostic Business of Thermo Fisher Scientific (2020-2025)
  • Table 85. Thermo Fisher Scientific Recent Developments
  • Table 86. Dian Diagnostic Basic Information List
  • Table 87. Dian Diagnostic Description and Business Overview
  • Table 88. Dian Diagnostic Pancreatic Cancer Diagnostic Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Pancreatic Cancer Diagnostic Business of Dian Diagnostic (2020-2025)
  • Table 90. Dian Diagnostic Recent Developments
  • Table 91. Key Raw Materials Lists
  • Table 92. Raw Materials Key Suppliers Lists
  • Table 93. Pancreatic Cancer Diagnostic Downstream Customers
  • Table 94. Pancreatic Cancer Diagnostic Distributors List
  • Table 95. Research Programs/Design for This Report
  • Table 96. Key Data Information from Secondary Sources
  • Table 97. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Pancreatic Cancer Diagnostic Product Picture
  • Figure 2. Global Pancreatic Cancer Diagnostic Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Pancreatic Cancer Diagnostic Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Pancreatic Cancer Diagnostic Report Years Considered
  • Figure 5. Global Pancreatic Cancer Diagnostic Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Pancreatic Cancer Diagnostic Revenue in 2024
  • Figure 7. Pancreatic Cancer Diagnostic Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Imaging Picture
  • Figure 9. Tumor Biomarker Picture
  • Figure 10. Biopsy Picture
  • Figure 11. Others Picture
  • Figure 12. Global Pancreatic Cancer Diagnostic Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 13. Global Pancreatic Cancer Diagnostic Sales Value Market Share by Type, 2024 & 2031
  • Figure 14. Product Picture of Hospitals
  • Figure 15. Product Picture of Clinics
  • Figure 16. Product Picture of Others
  • Figure 17. Global Pancreatic Cancer Diagnostic Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 18. Global Pancreatic Cancer Diagnostic Sales Value Market Share by Application, 2024 & 2031
  • Figure 19. North America Pancreatic Cancer Diagnostic Sales Value (2020-2031) & (US$ Million)
  • Figure 20. North America Pancreatic Cancer Diagnostic Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Europe Pancreatic Cancer Diagnostic Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Europe Pancreatic Cancer Diagnostic Sales Value by Country (%), 2024 VS 2031
  • Figure 23. Asia Pacific Pancreatic Cancer Diagnostic Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. Asia Pacific Pancreatic Cancer Diagnostic Sales Value by Region (%), 2024 VS 2031
  • Figure 25. South America Pancreatic Cancer Diagnostic Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. South America Pancreatic Cancer Diagnostic Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Middle East & Africa Pancreatic Cancer Diagnostic Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. Middle East & Africa Pancreatic Cancer Diagnostic Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Key Countries/Regions Pancreatic Cancer Diagnostic Sales Value (%), (2020-2031)
  • Figure 30. United States Pancreatic Cancer Diagnostic Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. United States Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
  • Figure 32. United States Pancreatic Cancer Diagnostic Sales Value by Application (%), 2024 VS 2031
  • Figure 33. Europe Pancreatic Cancer Diagnostic Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. Europe Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
  • Figure 35. Europe Pancreatic Cancer Diagnostic Sales Value by Application (%), 2024 VS 2031
  • Figure 36. China Pancreatic Cancer Diagnostic Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. China Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
  • Figure 38. China Pancreatic Cancer Diagnostic Sales Value by Application (%), 2024 VS 2031
  • Figure 39. Japan Pancreatic Cancer Diagnostic Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. Japan Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
  • Figure 41. Japan Pancreatic Cancer Diagnostic Sales Value by Application (%), 2024 VS 2031
  • Figure 42. South Korea Pancreatic Cancer Diagnostic Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. South Korea Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
  • Figure 44. South Korea Pancreatic Cancer Diagnostic Sales Value by Application (%), 2024 VS 2031
  • Figure 45. Southeast Asia Pancreatic Cancer Diagnostic Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. Southeast Asia Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
  • Figure 47. Southeast Asia Pancreatic Cancer Diagnostic Sales Value by Application (%), 2024 VS 2031
  • Figure 48. India Pancreatic Cancer Diagnostic Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. India Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
  • Figure 50. India Pancreatic Cancer Diagnostic Sales Value by Application (%), 2024 VS 2031
  • Figure 51. Pancreatic Cancer Diagnostic Industrial Chain
  • Figure 52. Pancreatic Cancer Diagnostic Manufacturing Cost Structure
  • Figure 53. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 54. Bottom-up and Top-down Approaches for This Report
  • Figure 55. Data Triangulation
  • Figure 56. Key Executives Interviewed